Search Patents
  • Two helix binders
    Patent number: 8198043
    Abstract: Provided herein are isolated polypeptides derived from the staphylococcal protein A protein B domain comprising a pair of anti-parallel alpha helices that are capable of binding a target. Also provided are nucleic acid sequences encoding such two helix binders, vectors containing the nucleic acid sequences encoding for two helix binders, and host cells transformed with vectors containing the nucleic acid sequences encoding for the two-helix binders. Also provided are methods of using the two helix binders.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: June 12, 2012
    Assignee: General Electric Company
    Inventors: Faisal Ahmed Syud, Jack Mathew Webster
  • Metastatic breast and colon cancer regulated genes
    Patent number: 6468790
    Abstract: Gene sequences as shown in SEQ ID NOS:1-85 have been found to be significantly associated with metastatic potential of cancer cells, especially breast and colon cancer cells. Methods are provided for determining the risk of metastasis of a tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-85, or a substantial portion thereof.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: October 22, 2002
    Assignee: Chiron Corporation
    Inventor: Klaus Giese
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7115731
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: October 3, 2006
    Assignee: sanofi pasteur limited/ sanofi pasteur limiteé
    Inventors: Lynn Doucette-Stamm, David Bush, Oiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Use of the cathelicidin LL-37 and derivatives thereof for wound healing
    Patent number: 8506994
    Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 13, 2013
    Assignee: Lipopeptide AB
    Inventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
  • Compositions and methods for the therapy and diagnosis of breast cancer
    Publication number: 20020085998
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.
    Type: Application
    Filed: April 13, 2001
    Publication date: July 4, 2002
    Applicant: Corixa Corporation
    Inventors: Yuqiu Jiang, Davin C. Dillon, Jennifer L. Mitcham, Jiangchun Xu, Susan L. Harlocker, William T. Hepler, Robert A. Henderson
  • Methods and compositions for retarding the development of atherosclerotic lesions
    Patent number: 6291437
    Abstract: A method for preventing or retarding the development atherosclerotic lesions or restenosis involves administering to a subject, preferably a human, an effective amount of an anti-viral composition directed against CMV, and optionally an anti-microbial composition directed against C. pneumoniae. These compositions may be conventional chemical anti-microbial pharmaceutics. Alternatively, the compositions may contain a cytomegalovirus (CMV) protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). Such compositions may contain an immunogenic C. pneumoniae protein or fragment thereof (or nucleic acid containing compositions expressing such protein or fragment). The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: September 18, 2001
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Eva Gonczol, Klara Berencsi
  • Polynucleotides encoding a human S100 protein
    Patent number: 5849528
    Abstract: The invention provides two human S100 proteins designated individually as S100P1 and S100P2 and collectively as S100P, and polynucleotides which identify and encode S100P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of S100P.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: December 15, 1998
    Assignee: Incyte Pharmaceuticals, Inc..
    Inventors: Jennifer L. Hillman, Olga Bandman, Neil C. Corley, Preeti Lal, Purvi Shah
  • Signal transduction protein TAB2
    Patent number: 7153664
    Abstract: A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-?B and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal transduction in TAB2 is useful as an anti-inflammatory drug.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: December 26, 2006
    Inventor: Kunihiro Matsumoto
  • Drug discovery methods
    Publication number: 20020192799
    Abstract: The present invention provides collections of polypeptides, where each polypeptide includes a region Xaan, wherein n is from about 5 to about 21, and each Xaa is independently a random amino acid. Polynucleotides encoding the polypeptides, are also provided, as are methods for identifying a polypeptide within a collection that prevents cell death after exposure to a pathogen or a toxin, and methods for identifying a polypeptide within a collection that binds a pathogen, a toxin, a polypeptide, or a polynucleotide. The present invention also provides methods for crystallizing a polypeptide.
    Type: Application
    Filed: October 15, 2001
    Publication date: December 19, 2002
    Applicant: Board of Regents, The University of Texas System
    Inventors: Stanley J. Watowich, Scott C. Weaver, Robert A. Davey
  • Two helix binders
    Patent number: 8318456
    Abstract: Provided herein are isolated polypeptides derived from the staphylococcal protein A protein B domain comprising a pair of anti-parallel alpha helices that are capable of binding a target. Also provided are nucleic acid sequences encoding such two helix binders, vectors containing the nucleic acid sequences encoding for two helix binders, and host cells transformed with vectors containing the nucleic acid sequences encoding for the two-helix binders. Also provided are methods of using the two helix binders.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: November 27, 2012
    Assignee: General Electric Company
    Inventors: Faisal Ahmed Syud, Jack Mathew Webster
  • Compositions and methods for the treatment of tumors
    Publication number: 20030113764
    Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
    Type: Application
    Filed: August 22, 2002
    Publication date: June 19, 2003
    Applicant: Genentech, Inc.
    Inventors: Sarah C. Bodary, Karen L. Fisher
  • MAGE-A3 peptides presented by HLA class II molecules
    Patent number: 7371845
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: May 13, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • COMPLEMENT DEPLETION USING RECOMBINANT HUMAN C-3 DERIVATIVES
    Publication number: 20090270324
    Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3 derivatives that are capable of forming C3 convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3 convertases, thus escaping the physiological degradation mechanisms.
    Type: Application
    Filed: April 23, 2009
    Publication date: October 29, 2009
    Inventors: JOHANNA KOLLN, EDZARD SPILLNER, REINHARD BREDEHORST
  • Chimeric interleukin 5-receptor/immunoglobulin polypeptides
    Patent number: 5712121
    Abstract: Chimeric polypeptides encoded by a DNA sequence having a first DNA subsequence coding for a fragment of at least one of the .alpha.-and/or .beta.-chain of the human interleukin-5 receptor, and a second DNA subsequence coding for the constant domains of a heavy--or a light-chain of a human immunoglobulin, or a fragment thereof are useful in treating illnesses with demonstrated eosinophilia.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: January 27, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rene Devos, Walter Fiers, Jose van der Heyden, Geert Plaetinck, Jan Tavernier
  • Oligmers which inhibit expression of collagen genes
    Patent number: 6156513
    Abstract: Oligomers which inhibit expression of a collagen gene are described. It is believed that each oligomer, when introduced into a cell, forms a transcription-inhibiting complex composed of the oligomer and the collagen-gene promoter region. The oligomer, preferably a phosphorothioate deoxyoligonucleotide or a ribonucleotide, preferably binds in the antiparallel orientation to the polypurine strand of a polypurine-polypyrimidine region of the promoter region of a mammalian .alpha.1(I) collagen gene.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: December 5, 2000
    Assignee: Ramareddy V. Guntaka
    Inventors: Ramareddy V. Guntaka, Karl T. Weber, Attilla Kovacs, Jagannadhachari Kandala
  • Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
    Patent number: 7256181
    Abstract: Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming a secreted protein expression system in vivo or ex vivo and administering the expression system to the mammalian recipient. The expression system and methods are useful for the localized and systemic delivery of interferons in situ.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: August 14, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: James G Barsoum, Albert X Qin
  • Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
    Patent number: 6180403
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr;-converting enzyme (TACE). Antisense oligonucleotides targeted to nucleic acids encoding TACE are preferred. Methods of using these oligonucleotides for inhibition of TACE expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TACE or TNF-&agr; are provided.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: January 30, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Shin Cheng Flournoy, C. Frank Bennett
  • Isolation, expansion and characterization of wharton's jelly mesenchymal stem cells
    Patent number: 10542743
    Abstract: The present invention relates to a method of isolating mesenchymal stem cells originated from Wharton's jelly (WJ-MSC) from single donor. The method for isolating and proliferating viable cells from Wharton's jelly wherein the method includes the steps of (a) obtaining umbilical cord tissue comprising of viable cells from Wharton's jelly, (b) isolating the viable cells in a sample collection media, (c) preparing a primary stock culture using the viable cells from step (b), (d) proliferating the primary stock culture from step (c) to obtain sub-cultured stocks, (e) harvesting the viable cells from the sub-cultured stocks from step (d) and (f) cryo-preserving the viable cells from step (e) under cryogenic conditions.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 28, 2020
    Assignee: HYGIEIA THERAPEUTICS SDN BHD
    Inventors: Vijayendran Govindasamy, Wijenthiran Kunasekaran, Naresh Waran Gnanasegaran
  • Insulator element having enhancer-blocking properties
    Publication number: 20030211581
    Abstract: The present invention relates to nucleic acid sequences that have insulator activity and the use of such sequences to prevent position effects on gene constructs transfected into cells. In one embodiment as shown in FIGS. 5A and 5B a vector is provided with a polylinker site (a) for insertion of a gene, wherein the polylinker site is flanked by one or more insulators (b). This insulator blocks enhancer effects on genes located downstream from the enhancer when the insulator is positioned between the enhancer and the gene.
    Type: Application
    Filed: November 26, 2002
    Publication date: November 13, 2003
    Inventors: John C. Herr, P. Prabhakara Reddi
  • RVP-1 variant differentially expressed in Crohn's disease
    Patent number: 6590089
    Abstract: The invention provides a mammalian cDNA which encodes a mammalian an RVP-1 variant. It also provides for the use of the cDNA, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of Crohn's disease. The invention additionally provides expression vectors and host cells for the production of the protein and a transgenic model system.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: July 8, 2003
    Assignee: Incyte Genomics, Inc.
    Inventors: Lynn E. Murry, Jennifer L. Hillman, Y. Tom Tang, Chandra Patterson